ATS American Thoracic Society
Recent Abstracts

Functional Assessment of Cancer Therapy - Lung (FACT-L)

Name of Questionnaire

Functional Assessment of Cancer Therapy – Lung, Version 4 (FACT-L v. 4)


FACT-G (core instrument) plus a Lung Cancer Subscale. Developer suggests that the FACT-L may also be useful for patients with lung diseases other than cancer.


David Cella


David Cella, Ph.D.
Research Professor
Institute for Health Services Research and Policy Studies
Northwestern University Director
Center on Outcomes, Research and Education
Evanston Northwestern Healthcare
1000 Central Street
Suite 101
Evanston, IL USA 60201
FAX: 847-570-1735



Cost & availability

No charge for use of the English versions. Contact D Cella for permission.



Time to complete

8 minutes

Number of items


Domains & categories


Name of categories/domains

Physical, social/family, emotional, and functional well-being; lung cancer subscale (symptoms, cognitive function, regret of smoking)

Scaling of items

Five-point scale from 0 (not at all) to 4 (very much)


Subscale scores added to obtain total score. Alternative scoring includes the Trial Outcome Index (TOI), which is the sum of the Physical, Functional, and Lung Cancer Subscales. The TOI is reported to be an efficient and precise summary index of physical and functional outcomes.


a. Test-retest/reproducibility Not reported
b. Internal consistency Reported1


Factor analysis confirmed the hypothesized multidimensional structure of instrument1. Correlated as expected with FLIC, M-CSDS social desirability measure, and Brief POMS1


Reported sensitivity to change in performance status over time1

Minimally important difference

2 points on the Lung Cancer Subscale1

Research use

Reported – paclitaxel in metastatic non-small cell lung cancer2, paclitaxel and carboplatin in advanced non-small cell lung cancer3.

Clinical use

Not reported


Chinese (Mainland), Danish, Dutch, English, Finnish, French, German, Hungarian, Italian, Norwegian, Spanish, Swedish


  1. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy -- Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12:199-220.
  2. Tester WJ, Jin PY, Reardon DH, et al. Phase II study of patients with metastatic non-small cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer 1997; 79:724-9.
  3. Roychowdhury DF, Desai P, Zhu Y-W. Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer. Semin Oncol 1997; 24:S12-37-S12-40.

Date of information

May 1999

Copyright © 2007 American Thoracic Society · Web Site Requirements
Questions or comments? Contact Us.